Soleno Therapeutics, Inc.Soleno Therapeutics, Inc.Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc.

No trades
See on Supercharts

SLNO fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends
SLNO has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company